MétaCan
Menu
Back to cohort
Record W4366602268 · doi:10.1111/bjh.18718

<scp>BSH</scp> 2023 Oral abstracts book

2023· article· ceb· W4366602268 on OpenAlexfundno aff

Bibliographic record

VenueBritish Journal of Haematology · 2023
Typearticle
Languageceb
FieldImmunology and Microbiology
TopicComplement system in diseases
Canadian institutionsnot available
FundersUniversity of Texas MD Anderson Cancer CenterCentre Hospitalier Universitaire de ToulouseUniversitätsklinikum Hamburg-EppendorfSyddansk UniversitetUniversité de ToulouseMemorial Sloan-Kettering Cancer CenterKarolinska InstitutetSt Vincent's Hospital MelbourneUniversité de LilleMassachusetts General HospitalUniversity of AlbertaCancer Research Institute
KeywordsMedicinePharmacology

Abstract

fetched live from OpenAlex

The complement C5 inhibitors eculizumab and ravulizumab are the current standards of care in patients with paroxysmal nocturnal haemoglobinuria (PNH), a rare chronic blood disorder.Ravulizumab provides the same clinical benefit as eculizumab in patients with PNH at a longer dosing interval (every 8 weeks [q8w] vs every 2 weeks [q2w]).Approximately 10%-15% of patients with PNH who receive the approved, fixed eculizumab dose (900 mg q2w) experience insufficient inhibition of intravascular haemolysis (IVH), characterised by breakthrough haemolysis (BTH) towards the end of the dosing interval.In such patients, increasing the eculizumab dose can be effective.However, currently there are no recommendations or clinical trial data regarding the impact of switching these patients to ravulizumab.Study 401 (NCT04320602) is an ongoing, phase 4, singlearm, multicentre trial designed to investigate the impact of switching treatment from fixed, high-dose IV eculizumab (1200 mg q2w) to weight-based IV ravulizumab q8w in adult (≥18 years of age; N = 18) patients with PNH.The primary endpoint is the proportion of patients who experience serum free C5-associated BTH (defined as ≥1 new or worsening symptom or sign of IVH with lactate dehydrogenase [LDH] levels ≥2 x upper limit of normal [ULN] and free C5 concentrations ≥0.5 μg/mL).Other endpoints include change in free C5 concentrations and LDH levels over time.This interim analysis describes data up to day 183 of follow-up.Data for 10/18 enrolled patients (55.6%) were available.From baseline to day 183, no instances of free C5-associated BTH were reported, free C5 concentrations remained below 0.5 μg/mL for all patients at all study timepoints, and LDH levels remained ≤1.5 × ULN in all patients.Up to day 183, 7/10 patients (70.0%) reported treatment-emergent adverse events that were mild (n = 3, 30.0%) or moderate (n = 4, 40.0%) in severity.BTH was reported in one patient which was deemed vaccine-related as two vaccinations were administered the day prior to the event.No elevated free C5 level was detected in the earliest available sample (0.11 μg/ mL, collected four days after the event) and the patient continued ravulizumab treatment.Results of this interim analysis showed that in a sample of ten patients with PNH, switching from high-dose IV eculizumab to standard, weight-based IV ravulizumab q8w was well tolerated.Up to day 183, no free C5-associated BTH was reported and the safety profile of ravulizumab was considered comparable to previously published studies.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.002
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow), Insufficient payload (model declined to judge)
Consensus categoriesInsufficient payload (model declined to judge)
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.317
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0020.002
Meta-epidemiology (narrow)0.0000.001
Meta-epidemiology (broad)0.0020.001
Bibliometrics0.0010.001
Science and technology studies0.0000.001
Scholarly communication0.0000.000
Open science0.0010.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0040.009

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.022
GPT teacher head0.275
Teacher spread0.253 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; both teacher heads agree on what is shown here.

Study designNot applicable
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2023
Admission routes1
Has abstractyes

Explore more

Same venueBritish Journal of HaematologySame topicComplement system in diseasesFrench-language works237,207